Iris Pauporté
Publications by Year
Research Areas
Cancer Genomics and Diagnostics, HER2/EGFR in Cancer Research, Breast Cancer Treatment Studies, Genetic factors in colorectal cancer, BRCA gene mutations in cancer
Most-Cited Works
- → Landscape of somatic mutations in 560 breast cancer whole-genome sequences(2016)2,312 cited
- → 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial(2013)337 cited
- → A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers(2016)157 cited
- → Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative(2014)133 cited
- → 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial(2019)126 cited
- → Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study(2015)67 cited
- → Abstract S5-3: PHARE Trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer(2012)37 cited
- → Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial(2014)30 cited
- → Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences(2019)19 cited
- → A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design(2022)18 cited